HSBC upgraded Dr. Reddy’s (RDY) to Buy from Hold with a price target of $16.90, up from $14.44. The firm believes semaglutide sales will help Dr. Reddy’s to return to earnings growth path within a year of launch in key markets. While a recent court order in India has restrained Dr. Reddy’s launch of semaglutide in export markets until the patent expiry of the reference brand in India in March 2026, the company will be among the first companies to launch in key markets opening up in 2026, the analyst tells investors in a research note. The firm sees a semaglutide-led earnings recovery for the company.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s Faces Tax Reassessment Order Post-Merger
- Dr. Reddy’s Laboratories to Engage with Investors in June 2025
- Dr. Reddy’s Laboratories Transfers Unclaimed Dividends to IEPF
- Dr. Reddy’s Laboratories Receives USFDA Observations After Recent Inspection
- Dr. Reddy’s Laboratories to Engage in Investor Conferences in May-June 2025